Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 43 CNY -4.04% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note

Acrobiosystems Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Acrobiosystems Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Income from Continuing Operations
ÂĄ147.6m
CAGR 3-Years
8%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Income from Continuing Operations
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Income from Continuing Operations
ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Income from Continuing Operations
ÂĄ1.2B
CAGR 3-Years
22%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Income from Continuing Operations
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Income from Continuing Operations
ÂĄ3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
48.56 CNY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Acrobiosystems Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
147.6m CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Income from Continuing Operations amounts to 147.6m CNY.

What is Acrobiosystems Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
67%

Over the last year, the Income from Continuing Operations growth was -26%. The average annual Income from Continuing Operations growth rates for Acrobiosystems Co Ltd have been 8% over the past three years , 67% over the past five years .

Back to Top